HER-2 Expression in Pancreatic Duct Adenocarcinoma

NCT06055647 | Completed

• 1 other identifier: Soh-Med-23-09-4PD
• Study Type: observational
• Target: 37
• Locations: 0 countries
• Sites: N/A

Brief Summary

Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their subsequent targeting by anti cancer therapeutic modalities may improve patient's survival.

Conditions

Pancreatic Adenocarcinoma

Keywords

HER-2; Pancreatic Duct Adenocarcinoma; Immunohistochemistry

Outcome Measures

Primary Outcomes (1)

• correlation of HRE-2 expression with clinical and pathological parameters

  levels of HER-2 expression will be correlated with clinical parameters (as patients' ages, sexes, tumor location), and pathological parameters (as tumor grades, stages, neural and vascular invasion).

  6 months

Interventions

immunohistochemical approach GENETIC

Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

• This study will be performed on archived formalin-fixed, paraffin-embedded tissue blocks that belonged to 37 patients who were admitted to Assuit and Sohag Oncology Centers and Sohag university hospital from January, 1st, 2017 to December, 31st, 2020. Patients' complaints included obstructive jaundice, abdominal pain and vomiting. Radiological assessment revealed heterogeneous suspicious pancreatic lesions from which tru-cut biopsies were obtained and examined by the standard staining method; hematoxylin and eosin (H\&E). Cases diagnosed as pancreatic carcinoma on the basis of tru-cut biopsies underwent pancreaticoduodenectomy (Whipple procedure) or distal pancreatectomy, depending on tumor location.

You may qualify if:

• Cases of PDAC who underwent radical operations.
• Tissue blocks with sufficient material.
• Cases with available clinical data.

You may not qualify if:

• Cases of pancreatic carcinoma other than PDAC.
• Patients who received preoperative chemotherapy or radiotherapy.
• Patients with PDAC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
• Cases with insufficient/destructed material.
• Patients with inadequate clinical data.

Sponsors & Collaborators

• Sohag University: lead

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Maisa H Mohammed, MD

Study Record Dates

• First Submitted: September 20, 2023
• First Posted: September 28, 2023
• Study Start: January 1, 2017
• Primary Completion: August 31, 2020
• Study Completion: December 31, 2020
• Last Updated: September 28, 2023

Record last verified: 2023-09